Literature DB >> 30711335

[Comparison of UICC and AJCC 8th edition TNM classifications in uropathology].

Eva Compérat1, Justine Varinot2, Caroline Eymerit2, Gladell P Paner3, Donna E Hansel4, Mahul B Amin5, Julien Moroch2.   

Abstract

The pTNM stage is one of the most important parameters in the handling of tumor patients. The pathologist plays a major role in the determination of the stage. The classifications undergo an evolution according to the state of art. The TNM system is used worldwide and allows to precise the tumor (T) and lymph node stage and the presence of distant metastasis. This system helps to stratify patient groups and determine their prognosis. In 2017, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) published their 8th edition. Unluckily several differences exist between both classifications. The UICC neglected to make several recommendations according to the International Society of Urological Pathology (ISUP) decisions, which organises the consensus in uropathology.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AJCC; Cancer; Classification; TNM; UICC; Uropathologie; Uropathology; classification

Mesh:

Year:  2019        PMID: 30711335     DOI: 10.1016/j.annpat.2018.12.005

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  2 in total

1.  Influence of American Society of Anesthesiologists Score on Oncologic Outcomes in Patients With Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Large-Sample Study in Two Institutions.

Authors:  Yichu Yuan; Yiqiu Wang; Nan Zhang; Xiawa Mao; Yiran Huang; Jiwei Huang; Na Ji
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

2.  Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris.

Authors:  André Oszwald; Gabriel Wasinger; Laura Larnaudie; Justine Varinot; Philippe Sebe; Olivier Cussenot; Eva Compérat
Journal:  World J Urol       Date:  2021-03-20       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.